Loading stock data…
$1.64+0.03 (+1.86%)
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
CEL-SCI Corporation in the Healthcare sector is trading at $1.64 with a market capitalization of $26M. Wall Street consensus targets $12.50 (2 analysts), implying a +662.2% move over the next 12 months. The stock is currently near its 52-week low of $0.89, remaining 37.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.56M↓ | -$5.33M↑ | -$5.37M↑ | -$6.03M↓ | -$5.49M |
| Net Income | -$5.67M↓ | -$5.47M | -$5.47M↑ | -$6.10M↓ | -$5.66M |
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has complete...